DrugPatentWatch Database Preview
Bausch And Lomb Company Profile
What is the competitive landscape for BAUSCH AND LOMB, and what generic alternatives to BAUSCH AND LOMB drugs are available?
BAUSCH AND LOMB has seventy-eight approved drugs.
There are twenty-five US patents protecting BAUSCH AND LOMB drugs.
There are two hundred and seven patent family members on BAUSCH AND LOMB drugs in forty-two countries and fifty-nine supplementary protection certificates in twelve countries.
Summary for Bausch And Lomb
| International Patents: | 207 |
| US Patents: | 25 |
| Tradenames: | 67 |
| Ingredients: | 54 |
| NDAs: | 78 |
| Patent Litigation for Bausch And Lomb: | See patent lawsuits for Bausch And Lomb |
Drugs and US Patents for Bausch And Lomb
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb | ZYLET | loteprednol etabonate; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 050804-001 | Dec 14, 2004 | RX | Yes | Yes | See Pricing | See Pricing | |||||
| Bausch And Lomb | LEVOBUNOLOL HYDROCHLORIDE | levobunolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 074307-001 | Mar 4, 1994 | DISCN | No | No | See Pricing | See Pricing | |||||
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | RX | Yes | Yes | 8,058,467 | See Pricing | Y | See Pricing | |||
| Bausch And Lomb | VITRASERT | ganciclovir | IMPLANT;IMPLANTATION | 020569-001 | Mar 4, 1996 | DISCN | No | No | See Pricing | See Pricing | |||||
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | RX | Yes | Yes | 7,629,345 | See Pricing | Y | See Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bausch And Lomb
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020583-001 | Mar 9, 1998 | 4,996,335*PED | See Pricing |
| Bausch And Lomb | ZYLET | loteprednol etabonate; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 050804-001 | Dec 14, 2004 | 4,996,335*PED | See Pricing |
| Bausch And Lomb | BESIVANCE | besifloxacin hydrochloride | SUSPENSION/DROPS;OPHTHALMIC | 022308-001 | May 28, 2009 | 6,699,492 | See Pricing |
| Bausch And Lomb | ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803-001 | Mar 9, 1998 | 5,747,061*PED | See Pricing |
| Bausch And Lomb | ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803-001 | Mar 9, 1998 | 4,996,335*PED | See Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAUSCH AND LOMB drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 0.5% | ➤ Subscribe | 2012-10-19 |
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | 2013-09-09 |
| ➤ Subscribe | Ophthalmic Solution | 0.07% | ➤ Subscribe | 2013-07-26 |
International Patents for Bausch And Lomb Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 2011009758 | See Pricing |
| China | 1612734 | See Pricing |
| World Intellectual Property Organization (WIPO) | 2004064828 | See Pricing |
| South Korea | 20060113753 | See Pricing |
| Mexico | PA01009718 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bausch And Lomb Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2163643 | CA 2015 00043 | Denmark | See Pricing | PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826 |
| 0227494 | 95C0013 | Belgium | See Pricing | PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910 |
| 2405015 | 300822 | Netherlands | See Pricing | PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326 |
| 1280520 | C300722 | Netherlands | See Pricing | PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720 |
| 1631293 | 2014/041 | Ireland | See Pricing | PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
